6.
Piekarz R, Frye R, Turner M, Wright J, Allen S, Kirschbaum M
. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27(32):5410-7.
PMC: 2773225.
DOI: 10.1200/JCO.2008.21.6150.
View
7.
Molina A, Zain J, Arber D, Angelopolou M, ODonnell M, Murata-Collins J
. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005; 23(25):6163-71.
DOI: 10.1200/JCO.2005.02.774.
View
8.
Heald P, Glusac E
. Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant. J Am Acad Dermatol. 2000; 42(2 Pt 1):283-5.
DOI: 10.1016/S0190-9622(00)90140-3.
View
9.
Duarte R, Canals C, Onida F, Gabriel I, Arranz R, Arcese W
. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28(29):4492-9.
DOI: 10.1200/JCO.2010.29.3241.
View
10.
Herbert K, Spencer A, Grigg A, Ryan G, McCormack C, Prince H
. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2004; 34(6):521-5.
DOI: 10.1038/sj.bmt.1704641.
View
11.
Heald P, Mehlmauer M, Martin A, Crowley C, Yocum R, Reich S
. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003; 49(5):801-15.
DOI: 10.1016/s0190-9622(03)01475-0.
View
12.
Girardi M, Heald P, Wilson L
. The pathogenesis of mycosis fungoides. N Engl J Med. 2004; 350(19):1978-88.
DOI: 10.1056/NEJMra032810.
View
13.
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R
. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996; 35(1):69-73.
DOI: 10.1016/S0190-9622(96)90499-5.
View
14.
Kannangara A, Levitan D, Fleischer Jr A
. Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil. J Drugs Dermatol. 2010; 9(8):1017-8.
View
15.
Ponte P, Serrao V, Apetato M
. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2009; 24(6):716-21.
DOI: 10.1111/j.1468-3083.2009.03500.x.
View
16.
Deeths M, Chapman J, Dellavalle R, Zeng C, Aeling J
. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005; 52(2):275-80.
DOI: 10.1016/j.jaad.2004.04.049.
View
17.
Lybaek D, Iversen L
. Pegylated liposomal doxorubicin in the treatment of mycosis fungoides. Acta Derm Venereol. 2006; 86(6):545-7.
DOI: 10.2340/00015555-0133.
View
18.
Jones G, Wilson L, Fox-Goguen L
. Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am. 2004; 17(6):1421-34.
DOI: 10.1016/s0889-8588(03)00108-4.
View
19.
Rook A, Heald P
. The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995; 9(5):997-1010.
View
20.
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E
. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19(2):376-88.
DOI: 10.1200/JCO.2001.19.2.376.
View